Dr. Lal Path Labs Ltd. has informed the Exchange regarding a press release dated April 30, 2026, titled "Press Release on Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2026".
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 12.8 pts more than Nifty Smallcap 250 and 12.0 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr Lal PathLabs reported Q4 FY26 revenue of Rs 703 Cr, marking a 16.6% year-on-year growth. EBITDA increased by 10.5% with an EBITDA margin of 26.6%. Profit After Tax (PAT) stood at Rs 132 Cr with a margin of 18.8%. The company announced a final dividend of Rs 4 per share (40%). As of March 31, 2026, the company maintains a strong cash position of Rs 1,526 Cr. The network includes 312 clinical laboratories, 7,727 Patient Service Centers, and 13,935 Pick-up Points across India.
The company delivered solid double-digit revenue and profit growth in Q4 FY26, with healthy margins and a strong cash position. The dividend declaration is positive for shareholders. The results reflect steady operational performance in the diagnostic services sector.